Medicare’s decision to deny coverage for the first new Alzheimer’s treatment the FDA has approved in nearly 20 years will hurt patients and slow research into a cure.
Medicare’s decision to deny coverage for the first new Alzheimer’s treatment the FDA has approved in nearly 20 years will hurt patients and slow research into a cure.
This website, like most media sites, uses small files called cookies to anonymously customize the advertising that you see. Learn more about how we use cookies in our cookie policy.
